Methandrostenolone, usually reffered to as Dianabol or dbol, was first produced and marketed by Ciba-Geigy in 1960. It was promoted as being highly anabolic, androgenic, with little progestational activity. Dianabol was also reported to enhance feelings of well-being. Dianabol was indicated for the treatment of disorders requiring increased protein synthesis and osteoporosis. There are many different pharmaceutical and generic varieties including Anabol and Naposim.

Dianabol has been shown to increase anaerobic glycolysis, which increases lactic acid build up in the body. This is beneficial because lactic acid is used by the muscles to form glycogen, which in turn provides energy in anaerobic metabolism. Lactic acid is also a key chemical in the disposal of dietary carbohydrates, which means you are less likely to get fat while using dianabol.

A study on osteoporosis showed that at a dosage of just 2.5mg per day for 9 months dianabol was more effective than calcium supplementation in reducing osteoporotic activity, it was also shown to increase muscle mass more effectively. Another study on osteoporosis which lasted 24 months, showed just how dianabol works on osteoporosis; dianabol increased total body calcium, and also total body potassium. The actions of calcium are very important, as it transports large numbers of amino acids and also creatine and these two things are vital in muscle growth. Potassium is also very important, as it assists in muscle contractions, transmitting nerve signals, and insulin release; so it is also a very anabolic substance.

One very interesting study (Radiomodifying effect of methandrostenolone on laryngeal cancer cells) showed that dianabol increases the sensitivity of laryngeal tumour cells to radiotherapy, and concluded 'recommending this hormone to be used during radiotherapy of patients with the laryngeal cancer'.

Dianabol has a relatively short half-life, between 3.2 and 4.5 hours, with maximum blood concentration occurring between 1 and 3 hours. Methandrostenolone and Methandienone are almost identical, the only difference being in the spatial configuration of their chemical structure. They are 17-alpha-alkylated compounds and therefore exert a significant strain in the liver function tests. There have been reports of the development of jaundice being attributed to methandrostenolone/methandienone and there have also been cases of liver carcinoma and andenoma associated with its use.

Therapeutic dose: 4 mg orally daily (pain relief in osteoporosis), 6 weeks on, 4 weeks off

Notice: The information below is intended to supplement the information provided by medically trained and certified professionals.